Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects


Abstract

Objective—To determine the efficacy, tolerability, and impact on quality of life and cognitive functioning of anticonvulsant prophylaxis with phenytoin or sodium valproate in patients after craniotomy.

Methods—A prospective, stratified, randomised, double blind single centre clinical trial was performed, comparing two groups of 50 patients each, who underwent craniotomy for different pathological conditions and who were treated for 1 year after surgery with either 300 mg phenytoin/day or 1500 mg sodium valproate/day. During the study period patients were seen in the outpatient clinic at 1.5, 3, 6, and 12 months, when medical history, adverse events, and drug plasma concentrations were evaluated. Neuropsychological functioning and quality of life were assessed on the last three visits. In cases of a seizure an EEG was performed, drug plasma concentration assessed, and medication subsequently increased.

Results—Of the 100 included patients 14 (seven in each group) experienced one or more postoperative seizures. Severity of the seizures was comparable in the two groups. In all patients, drug plasma concentrations were in the low or subtherapeutic ranges at the time of the first postoperative seizure. Five patients in the phenytoin group and two in the valproate group had to stop their treatment due to drug related adverse events. Sixty patients completed the 12 month period. Analysis of neuropsychological and quality of life data showed no significant differences.

Conclusion—For efficacy, tolerability, impact on cognitive functioning, and quality of life, no major differences were found between phenytoin and valproate prophylaxis. Valproate is an alternative for anticonvulsant prophylaxis in patients after craniotomy.

Keywords: craniotomy; sodium valproate; phenytoin; seizures; quality of life; cognitive functioning
cognitive assessment are shown in parentheses.

* Other brain tumors were a pituitary adenoma, neurocytoma, schwannoma, and a haemangioblastoma in the phenytoin group, and two colloid cysts, a pituitary adenoma, and a hamartoma in the valproate group. SAH=Subarachnoid haemorrhage. The number of patients with complete cognitive assessment are shown in parentheses.

**Table 1** Baseline characteristics of study groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Phenytoin</th>
<th>Valproate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of cases</td>
<td>50</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>Men/women</td>
<td>26 / 24</td>
<td>21 / 29</td>
<td>47 / 53</td>
</tr>
<tr>
<td>Mean age/ range (y)</td>
<td>55 / 21–78</td>
<td>51 / 21–77</td>
<td>53 / 21–78</td>
</tr>
<tr>
<td>Completed 12 months</td>
<td>29 (27)</td>
<td>31 (28)</td>
<td>60 (55)</td>
</tr>
<tr>
<td>Pathology:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant glioma</td>
<td>7 (0)</td>
<td>11 (2)</td>
<td>18 (2)</td>
</tr>
<tr>
<td>Low grade glioma</td>
<td>2 (1)</td>
<td>1 (0)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Metastasis</td>
<td>9 (2)</td>
<td>4 (1)</td>
<td>13 (3)</td>
</tr>
<tr>
<td>Meningioma</td>
<td>7 (6)</td>
<td>8 (7)</td>
<td>15 (13)</td>
</tr>
<tr>
<td>Other tumours*</td>
<td>4 (4)</td>
<td>4 (4)</td>
<td>8 (8)</td>
</tr>
<tr>
<td>Traumatic head injury</td>
<td>2 (1)</td>
<td>2 (1)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Chronic subdural haematoma</td>
<td>1 (0)</td>
<td>2 (2)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Intracranial haemorrhage</td>
<td>3 (2)</td>
<td>1 (1)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Aneurysmal SAH</td>
<td>15 (11)</td>
<td>13 (5)</td>
<td>28 (16)</td>
</tr>
<tr>
<td>Cavernosa</td>
<td>0 (0)</td>
<td>4 (4)</td>
<td>4 (4)</td>
</tr>
</tbody>
</table>

* Other brain tumors were a pituitary adenoma, neurocytoma, schwannoma, and a haemangioblastoma in the phenytoin group, and two colloid cysts, a pituitary adenoma, and a hamartoma in the valproate group. SAH=Subarachnoid haemorrhage. The number of patients with complete cognitive assessment are shown in parentheses.

**Patients and methods**

**DESIGN**

A single centre, stratified, randomised, double blind, comparative clinical trial was performed. The procedures followed were approved by the institutional ethics committee, and were in accordance with the Helsinki Declaration of 1975, as revised in 1983. Randomisation started in August 1993 and was stopped after reaching the preset inclusion of 100 patients—50 patients in each group—in August 1995. Patients were stratified depending on the type of their intracranial pathology: brain tumour, trauma, or vascular lesions. Random allocation was carried out with sealed envelopes for each stratum, each patient receiving a separate treatment number determining whether the patient was treated with phenytoin or valproate. Sanofi Winthrop Recherche, Montpellier, France provided all pre-coded packaged material.

**CRITERIA FOR INCLUSION**

Patients could be included if they would undergo supratentorial surgery for one of the above mentioned pathological conditions, were aged between 18 and 80 years, and had given written informed consent. Exclusion criteria were: a life expectancy of less than 6 months, preoperative use of anticonvulsant drugs for more than 3 months, a history of epileptic seizures apart from seizures caused by the presenting disease (this was the case in 23 patients, most of whom had a glioma), chronic use of psychopharmaceuticals, alcohol or drug misuse, severe psychiatric illness, and participation in an experimental drug trial. The demographic data of the included patients are presented in **Table 1**. In view of the few trauma cases, the strata were collapsed to two categories (tumour v other).

**Drug treatment**

Intravenous administration of 100 mg phenytoin thrice daily or 500 mg valproate thrice daily was started immediately postoperatively in the recovery room. We did not use loading doses. As soon as possible, patients switched to the same regimen in oral formulation of phenytoin or valproate (Depakine chrono®). In selected cases of critically ill patients with a long stay in the intensive care unit, medication was administered as syrup via a nasogastric tube. No other maintenance anticonvulsant medication, including barbiturates, hypnotics, and benzodiazepines, was acceptable during the study. Otherwise, the patient was withdrawn from the study and considered a treatment failure.

In cases of adverse events, intoxication or toxic drug plasma concentrations (≥200 mg/l valproate and 50 mg/l phenytoin) the medication regimen was adjusted at the judgement of the unblinded investigator (DGAK), who was not otherwise involved in the data collection. Subsequent control plasma concentrations were taken. In case of a seizure a detailed description of the event was obtained to classify it according to the ILAE international classification and elaborate its severity according to the national hospital seizure severity score NHS3.30 31 If possible, a drug plasma concentration was taken, an EEG was performed, and medication was adjusted.

**Pharmacokinetic calculations**

Average individual steady state serum concentrations were calculated using the population pharmacokinetic software programme MWPharm with general population models for phenytoin and valproic acid.32 Models were fit to the patient data (weight, height, age) and serum concentration data using Bayesian regression to obtain the individual pharmacokinetic parameters (phenytoin: volume of distribution and elimination rate constant). These individualised pharmacokinetic parameters were used to calculate individual steady state serum concentrations.

**Assessments**

During the recovery period, vital signs, adverse events, and a drug plasma concentration on the third postoperative day were assessed. Patients were followed up for 1 year, during which time
period they were controlled by the study coordinator (LFMB) at the outpatient clinic at 1.5, 3, 6, and 12 months for: medical history including possible seizures and adverse effects of the anticonvulsant, physical examination, Karnofsky performance status, and laboratory tests including drug plasma concentration. At 3, 6, and 12 months neuropsychological and quality of life tests were administered.

NEUROPSYCHOLOGICAL TESTS

Neuropsychological tests consisted of two standard clinical tasks and three computerised tasks; the last were derived from a battery designed for the testing of epileptic patients and have been shown to be useful in the study of anticonvulsant drugs.36–38

(1) Serial word learning38

The learning of a list of 15 orally presented words is measured by immediate recall (sum of 5 trials), delayed recall after an interval of 20 minutes, and recognition (yes/no choice in a list of 30 words).

(2) Categoric word fluency, derived from a Dutch intelligence test39

The patient is required to name as many animals and professions as possible, one minute each.

(3) Simple auditory reaction time

The space bar must be pressed as fast as possible with the preferred hand in response to an auditory stimulus. Performance is measured as the median reaction time in 30 trials.

(4) Binary choice task

The patient must press a left or right key in response to respectively a green square on the left side and a red square on the right side of the screen, appearing in random alternation. Each response is immediately followed by a new stimulus. Performance is measured by the average reaction time in 60 trials.

(5) Visual searching task

A non-verbal design in the centre of the screen must be matched to one out of 24 surrounding patterns. Performance is measured by the average search time in 24 trials.

The Dutch version of the National adult reading test,39 a measure of vocabulary insensitive to brain dysfunction,39 was administered on the visit at 3 months to estimate premorbid intelligence.

QUALITY OF LIFE MEASURES

Emotional status was measured with a shortened Dutch version of the profile of mood states (POMS),4041 which yields five subscales: depression, anger, fatigue, vigour, and tension. Fatigue was additionally assessed with the more extensive fatigue severity scale (FSS).41 Furthermore, a self developed questionnaire was administered, previously employed in a study in patients with low grade glioma,42 referring to perceived dependency in activities of daily living (six three point items), physical complaints (seven three point items), cognitive restrictions (five five point items), sense of restriction in daily functioning (one five point item), satisfaction with health (one five point item), and general wellbeing (one five point item).

ANALYSIS

At the end of the study, recorded variables for each individual patient were elaborated and analysed. Outcome measurements for the study were: efficacy as determined by the occurrence of seizures and their severity score following the national hospital seizure severity score, clinical tolerability, cognitive functioning evaluated by neuropsychological tests, and quality of life. For efficacy, seizure severity, and tolerability, group differences were tested with t tests and non-parametric tests (χ² or Fisher's exact, Mann-Whitney U test) as appropriate. Neuropsychological and quality of life data were analysed with repeated measurements analysis of variance (ANOVA), using polynomial contrasts. Independent variables were group (phenytoin v valproate) and stratum (tumour v other). The outcomes considered—reflecting possible differential medication effects—were the overall group difference (phenytoin v valproate) and the linear or quadratic group by visit interaction. This analysis was restricted to 55 patients who could be fully tested on all three occasions (table 1), which excluded 11 patients who were tested partially and 24 who could not be tested at all. Due to a high mortality, the excluded group contained most patients with high grade gliomas or metastatic tumours. A power analysis indicated that, given the design and group size, the statistical power to show significance for a difference of 0.5 SD at the two tailed 5% level was 0.87. Significance was accepted at the two tailed 5% level.

Results

DEMOGRAPHY

No significant differences were found in baseline characteristics (sex, age, pathology, and history of preoperative seizures) of the medicine groups, either in the total sample or in the subgroups with complete preoperative seizures of the medicine groups, either in the total sample or in the subgroups with complete preoperative seizures of the medicine groups, either in the total sample or in the subgroups with complete preoperative seizures of the medicine groups, either in the total sample or in the subgroups with complete preoperative seizures of the medicine groups, either in the total sample or in the subgroups with complete preoperative seizures of the medicine groups, either in the total sample or in the subgroups with complete preoperative seizures.
Postoperative anticonvulsant prophylaxis

Table 2  Attrition by medicine group and stratum

<table>
<thead>
<tr>
<th></th>
<th>Phenytoin</th>
<th>Valproate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour</td>
<td>Other</td>
<td>Tumour</td>
<td>Other</td>
</tr>
<tr>
<td>Completed trial</td>
<td>13</td>
<td>16</td>
<td>15</td>
</tr>
<tr>
<td>Died in week 1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>2–6</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>7–12</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>13–26</td>
<td>3</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>27–52</td>
<td>4</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Intercurrent illness</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Adverse drug reaction</td>
<td>1</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Withdrew informed consent</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Lost to follow up</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

Postoperative anticonvulsant prophylaxis

The number of patients with postoperative seizures who also had preoperative seizures are shown in parentheses.

Table 3  Cases with seizures

<table>
<thead>
<tr>
<th></th>
<th>Phenytoin</th>
<th>Valproate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preoperative</td>
<td>11</td>
<td>12</td>
<td>23</td>
</tr>
<tr>
<td>Simple partial</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Generalised</td>
<td>9</td>
<td>9</td>
<td>18</td>
</tr>
<tr>
<td>Simple partial and generalised</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Postoperative</td>
<td>7 (2)</td>
<td>7 (3)</td>
<td>14 (5)</td>
</tr>
<tr>
<td>Simple partial</td>
<td>3 (1)</td>
<td>2 (1)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>Generalised</td>
<td>2 (1)</td>
<td>4 (2)</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Simple partial and generalised</td>
<td>2 (0)</td>
<td>1 (0)</td>
<td>3 (0)</td>
</tr>
</tbody>
</table>

Pathology associated with postoperative seizures:

- Malignant glioma
- Metastasis
- Low grade glioma
- Meninigioma
- Neurocytoma
- Cavernoma
- Traumatic head injury
- Aneurysm ant comm artery

Time after operation (weeks) of first seizure.

found in time to first seizure between phenytoin and valproate users (Mann-Whitney U test). Between the two groups the severity of the seizures (according to the NHS-3) showed no significant difference (Mann-Whitney U test). In patients with multiple seizures, neither a decrease nor an increase in severity over time could be found.

SEIZURE ASSOCIATIONS

In nine of the 14 patients who experienced postoperative seizures, a primary or secondary brain malignancy was the underlying pathology. In four cases (two in each group), a recurrent tumour (after 11, 17, 23, and 29 weeks respectively) was concurrent with seizure presentation. Seizures were associated with a complicated postoperative course in four patients (two ischaemia, one oedema, one haemorrhage). In six of the 14 patients with postoperative seizures the occurrence of seizures was not related to either perioperative complications or radiological recurrence.

ADVERSE EFFECTS

Seven patients had to stop treatment because of drug related side effects, five patients in the phenytoin group versus two in the valproate group (not significant). Four patients treated with phenytoin showed a hypersensitivity skin reaction, occurring between 6 days and 4 weeks after the start of treatment. After cessation of the therapy recovery of the patients was without sequelae within 1–2 weeks. In both study groups patients had transient gastrointestinal complaints. In one patient treated with phenytoin the nausea was persistent despite treatment with several antiemetics, and caused withdrawal from the trial. Also in both groups equal numbers of liver function disturbances were found (total number of patients six). In one patient treated with valproate there was a marked rise in liver enzymes which necessitated withdrawal from the trial. A contributing factor could have been the pre-existing minor disturbance of liver function associated with the use of amiodarone. In all patients liver enzymes returned to normal values, without lasting consequences to the patients. In one patient receiving valproate a thrombopenia necessitated discontinuation of treatment. Other known adverse effects of the therapeutic range (<8 mg/l phenytoin, <50 mg/l valproate) in all seven patients of the phenytoin group and four out of the seven patients in the valproate group; in the other three valproate patients drug concentrations were below 62 mg/l. In the 10 patients whose first seizure occurred more than 1 day after the operation, the mean drug plasma concentrations were 5.1 (SD 2.3) mg/l for those on phenytoin (n=5) and 56.8 (SD 10.0) mg/l for those on valproate (n=5). In patients without postoperative seizures these values were 11.7 (SD 6.7) (phenytoin, n=43) and 70 (SD 13) (valproate, n=43), both significantly higher (p<0.05, t test). For the total sample, excluding patients with a change in medication, the steady state concentrations of phenytoin and valproate were 10.9 (SD 6.6) mg/l (range 4–28) and 68 (SD 13) mg/l (range 44–100) respectively.

DOSAGE REGIMEN CHANGES

The initial therapy regimen of tablets thrice daily remained unchanged in 81 patients, 38 of them receiving phenytoin, 43 of them taking valproate. Significantly more patients on phenytoin had to reduce their drug regimen to twice daily because of toxic drug plasma concentrations, seven out of 50 patients on phenytoin compared with no patients out of 50 on valproate (p=0.012, Fisher’s exact test). In five patients receiving phenytoin and in seven patients receiving valproate dosages had to be increased after seizures.

One patient in the phenytoin group and two in the valproate group experienced a single seizure (with seizure freedom after change of dosage). The other 11 patients had multiple seizures despite increased dosages. Subtherapeutic dosages were in themselves no reason to increase the dosage, whereas toxic dosages were.

Drug plasma concentrations taken after the first postoperative seizure were below the usual
The data are derived from 55 patients (27 with phenytoin, 28 with valproate) whose assessment was complete. ADL=Activities of daily living.

Table 4 Neuropsychological test results

<table>
<thead>
<tr>
<th></th>
<th>3 Months</th>
<th></th>
<th>6 Months</th>
<th></th>
<th>12 Months</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Phenytoin</td>
<td>Valproate</td>
<td>Phenytoin</td>
<td>Valproate</td>
<td>Phenytoin</td>
<td>Valproate</td>
</tr>
<tr>
<td>average</td>
<td>M</td>
<td>SD</td>
<td>M</td>
<td>SD</td>
<td>M</td>
<td>SD</td>
</tr>
<tr>
<td>Word learning, immediate recall</td>
<td>34.7</td>
<td>13.8</td>
<td>37.8</td>
<td>11.0</td>
<td>39.0</td>
<td>15.7</td>
</tr>
<tr>
<td>Word learning, delayed recall</td>
<td>6.5</td>
<td>4.0</td>
<td>7.3</td>
<td>3.3</td>
<td>8.0</td>
<td>4.1</td>
</tr>
<tr>
<td>Word learning, recognition</td>
<td>27.1</td>
<td>3.4</td>
<td>27.8</td>
<td>1.7</td>
<td>27.1</td>
<td>3.0</td>
</tr>
<tr>
<td>Word fluency</td>
<td>32.2</td>
<td>13.2</td>
<td>34.6</td>
<td>12.2</td>
<td>35.4</td>
<td>13.5</td>
</tr>
<tr>
<td>Auditory reaction time (ms)</td>
<td>347</td>
<td>247</td>
<td>328</td>
<td>189</td>
<td>320</td>
<td>170</td>
</tr>
<tr>
<td>Visual search (s)</td>
<td>660</td>
<td>446</td>
<td>580</td>
<td>219</td>
<td>647</td>
<td>516</td>
</tr>
</tbody>
</table>

Table 5 Quality of life measures

<table>
<thead>
<tr>
<th></th>
<th>3 Months</th>
<th></th>
<th>6 Months</th>
<th></th>
<th>12 Months</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Phenytoin</td>
<td>Valproate</td>
<td>Phenytoin</td>
<td>Valproate</td>
<td>Phenytoin</td>
<td>Valproate</td>
</tr>
<tr>
<td>Mean</td>
<td>M</td>
<td>SD</td>
<td>M</td>
<td>SD</td>
<td>M</td>
<td>SD</td>
</tr>
<tr>
<td>Satisfaction with health</td>
<td>3.3</td>
<td>0.9</td>
<td>3.1</td>
<td>1.2</td>
<td>3.8</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Discussion

Despite the frequent occurrence of seizures after a craniotomy the routine use of anticonvulsants as prophylaxis is controversial. Anticonvulsant prophylaxis for the prevention of seizures is recommended in general if the risk of seizures exceeds 10%-15%, which is the anticipated incidence of serious adverse drug effects.1 Prophylaxis is also advised when a single seizure may have disastrous consequences or when seizures are a major impediment to a patient’s return to normal activity.

The choice of anticonvulsant prophylaxis should be determined on one hand by the risks and consequences of seizures during the immediate postoperative period and during the later course, and on the other hand by the efficacy and tolerability of each anticonvulsant drug. Furthermore, it should still be determined when to start and withdraw prophylactic medication and what dosages should be prescribed.

In this study, a randomised clinical trial evaluating the clinical impact of two widely used anticonvulsants as prophylaxis after craniotomy, we found no significant differences in efficacy and tolerability between the two treatment groups: both in the phenytoin group and the sodium valproate group the same number of patients had seizures. In both groups the seizures also had the same severity impact on patients.

Our data are comparable with the data from the double blind randomised trial carried out by North et al8 who had a similar study population and follow up of 1 year. In 281 postcraniotomy patients they compared 100 mg phenytoin thrice daily with placebo. Phenytoin significantly reduced seizure incidence...
Postoperative anticonvulsant prophylaxis

479

In a randomised trial, Foy et al compared phenytoin or carbamazepine treatment with placebo for a period of 6 or 24 months and found a reduction of almost 10% in postoperative seizures in the anticonvulsant groups. The differences were not statistically significant, but confidence limits were relatively wide. Because no formulation of carbamazepine for intravenous use exists, this limits its use to patients who are able to swallow and have reliable gastrointestinal absorption. A difference with our trial set up was the absence of regular drug monitoring in their patients. In the 217 patients (80%) in whom some concentrations were monitored, concentrations of carbamazepine usually were within the therapeutic range, but—as in our study—a significant proportion of phenytoin concentrations were below the therapeutic range.

Our standard treatment regimen of 100 mg phenytoin or 500 mg valproate three times daily resulted in average blood concentrations of 11.7 mg/l and 57 mg/l respectively in patients without seizures (most patients); the patients who experienced seizures had significant lower blood concentrations. North et al. also stress the importance of achieving therapeutic anticonvulsant concentrations. In their trial, seven of the nine patients experiencing generalised convulsions had subtherapeutic drug concentrations. By contrast with our findings, in which most patients irrespective of seizure type had serum drug concentrations below the regular therapeutic ranges, North et al found a therapeutic concentration in seven of nine patients with focal seizures. Because both phenytoin and valproate are effective in preventing partial as well as generalised tonic-clonic seizures, these differences in protection between these seizure types cannot be easily explained.

Seizures in the immediate postoperative period are correlated with the preoperative lesion, the site of the lesion, postoperative lesions, and subtherapeutic drug concentration. We started treatment directly postoperatively when patients arrived at the recovery room. Six patients experienced their first seizure during the first postoperative week, four had a first seizure already at the day of the operation. In one patient the seizure was associated with a postoperative haemorrhage.

In a placebo controlled randomised trial on phenytoin Lee et al studied immediate and early seizures in 374 patients. During the first 3 days, 11 patients (2.9%) developed seizures: two in the phenytoin group and nine in the placebo group; this difference was not significant. Because 80% of the immediate seizures occurred within 20 minutes after surgery they recommended anticonvulsant drugs to be given at least 20 minutes before completion of wound closure. The advised therapeutic loading dose for phenytoin varies between 7–10 mg/kg. For sodium valproate a schedule of an intravenous 10 mg/kg bolus and 0.6 mg/kg/hour sodium valproate is advised. Because these anticonvulsant drugs need about 1 week to reach a steady state drug plasma concentration, an even better option could be to start 1 week preoperatively, whenever possible, as was advised by North et al.

In our study, nine (64%) of the 14 patients who experienced seizures had their first seizure within 3 months after the operation. Of the 76 patients at risk at 3 months, five (7%) had their seizure presentation within 6 months. These findings are in line with the data from North et al, in which three quarters of all seizures occurred within 3 months. With a longer follow up, the incidence in postoperative seizures increases depending on the underlying pathology: in cerebral abscess, first year incidence was 30%, rising to 72% after a median follow up of 11 years. Although some authors advocate prophylaxis during one to several years, in the long term, the benefits of seizure prevention may not outweigh the risks of chronic anticonvulsant use. Our study supports the idea of stopping prophylaxis after a 6 month period. Further elucidation on this matter should be obtained by a prospective study.

For toxicity and adverse effects, in our study more patients had to stop treatment due to toxicity in the phenytoin group than in the valproate group (five phenytoin v two valproate). The 8% incidence of hypersensitive skin reactions associated with phenytoin use we found is well comparable with the literature. Other known adverse effects of both anticonvulsant drugs—for example, gastrointestinal complaints, liver function disturbances, anaemia (phenytoin), and weight gain (valproate)—were comparable with data reported in the literature and were in most cases of minor impact. Only in two patients (one in each group) did it necessitate cessation of trial medication.

With respect to the psychological evaluation, patients with valproate showed a slight but consistent advantage on cognitive measures, whereas they tended to complain more of tension and fatigue. Whether larger group sizes would have led to significant differences is doubtful. It must be taken into account that the patients had varied and often severe brain disease, and it is unlikely that the severity of the cognitive effects was entirely equated by the randomisation procedure. In this respect an increase in group sizes might well lead to smaller differences. At any rate the differential effect of phenytoin and valproate on cognition and quality of life seems negligible in comparison with the impact of disease and its treatment.

In conclusion, we compared two regularly used anticonvulsant drugs with both oral and intravenous formulation at standard dosages. No difference in either efficacy or impact on cognitive functioning and quality of life was found between the two drugs. In favour of valproate was a lower number of patients showing toxic serum drug concentrations. Both drugs can be recommended for the use of postoperative prophylaxis. For protection of...
immediate postoperative seizures it is advised to start treatment 1 week before surgery, or if that is not possible to start treatment with a loading dose at least 20 minutes before wound closure.

A timely detection and adjustment of subtherapeutic concentrations is important; this requires frequent monitoring of blood concentrations, starting in the first postoperative week. The anticonvulsant prophylaxis can be stopped after 6 months.

Part of this study was presented at the 11th International Congress of Neurological Surgery, held 4–11 July 1997 in Amsterdam, The Netherlands. Drugs and an unrestricted educational grant were supplied by Sanofi Winthrop S.A. and Gouver van Wijnalden 48, 3114 RS Maassluis, The Netherlands.